Cargando…

Distinct characteristics of central serous chorioretinopathy according to gender

To investigate the differences in clinical and genetic characteristics between males and females with central serous chorioretinopathy (CSC). Consecutive 302 patients (mean age; 56.3 ± 11.7, male/female: 249/53) with CSC were evaluated on the initial presentation. All CSC patients underwent fluoresc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoneyama, Seigo, Fukui, Ayumi, Sakurada, Yoichi, Terao, Nobuhiro, Shijo, Taiyo, Kusada, Natsuki, Sugiyama, Atsushi, Matsubara, Mio, Fukuda, Yoshiko, Kikushima, Wataru, Parikh, Ravi, Mabuchi, Fumihiko, Sotozono, Chie, Kashiwagi, Kenji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217960/ https://www.ncbi.nlm.nih.gov/pubmed/35732691 http://dx.doi.org/10.1038/s41598-022-14777-8

Ejemplares similares

Association between Polygenic Risk Score and One-Year Outcomes Following As-Needed Aflibercept Therapy for Exudative Age-Related Macular Degeneration
por: Shijo, Taiyo, et al.
Publicado: (2020)

Cuticular drusen presenting with central serous chorioretinopathy in both eyes: A case report
por: Hosoda, Shuhei, et al.
Publicado: (2022)

Characteristics of intermediate age-related macular degeneration with hyperreflective foci
por: Kikushima, Wataru, et al.
Publicado: (2022)

Changes in Choroidal Thickness and Structure in Preeclampsia with Serous Retinal Detachment
por: Fukui, Ayumi, et al.
Publicado: (2023)

Reply to Marino et al. Does Subretinal Fluid Influence Choroidal Thickness (ChT) and Structure in Preeclampsia with Serous Retinal Detachment? Comment on “Fukui et al. Changes in Choroidal Thickness and Structure in Preeclampsia with Serous Retinal Detachment. J. Clin. Med. 2023, 12, 609”
por: Fukui, Ayumi, et al.
Publicado: (2023)

Genetic factors associated with response to as-needed aflibercept therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
por: Yoneyama, Seigo, et al.
Publicado: (2020)

Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity
por: Kikushima, Wataru, et al.
Publicado: (2021)

Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy
por: Fukuda, Yoshiko, et al.
Publicado: (2020)

Correction: Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Kikushima, Wataru, et al.
Publicado: (2020)

Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Wataru, Kikushima, et al.
Publicado: (2020)

Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Kikushima, Wataru, et al.
Publicado: (2017)

Comparison of the 1-Year Visual and Anatomical Outcomes between Subthreshold Red (670 nm) and Yellow (577 nm) Micro-Pulse Laser Treatment for Diabetic Macular Edema
por: Kikushima, Wataru, et al.
Publicado: (2021)

Incidence and risk of advanced age-related macular degeneration in eyes with drusenoid pigment epithelial detachment
por: Shijo, Taiyo, et al.
Publicado: (2022)

Clinical and genetic characteristics of pachydrusen in patients with exudative age-related macular degeneration
por: Fukuda, Yoshiko, et al.
Publicado: (2019)

Drusenoid Pigment Epithelial Detachment: Genetic and Clinical Characteristics
por: Shijo, Taiyo, et al.
Publicado: (2021)

CILIOCHOROIDAL EFFUSION IN CENTRAL SEROUS CHORIORETINOPATHY
por: Terao, Nobuhiro, et al.
Publicado: (2022)

Incidence and risk factors of retreatment after three-monthly aflibercept therapy for exudative age-related macular degeneration
por: Kikushima, Wataru, et al.
Publicado: (2017)

Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy
por: Fukuda, Yoshiko, et al.
Publicado: (2021)

A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result
por: Kikushima, Wataru, et al.
Publicado: (2023)

Scleral Thickness in Steroid-Induced Central Serous Chorioretinopathy
por: Sawaguchi, Shota, et al.
Publicado: (2022)

Prevalence and Genetic Characteristics of Geographic Atrophy among Elderly Japanese with Age-Related Macular Degeneration
por: Sakurada, Yoichi, et al.
Publicado: (2016)

Association between Corneal Higher-Order Aberrations Evaluated with a Videokeratographer and Corneal Surface Abnormalities in Dry Eye
por: Kusada, Natsuki, et al.
Publicado: (2023)

Relationship Between Scleral Thickness and Choroidal Structure in Central Serous Chorioretinopathy
por: Imanaga, Naoya, et al.
Publicado: (2023)

Response to photodynamic therapy combined with intravitreal aflibercept for polypoidal choroidal vasculopathy depending on fellow-eye condition:2-year results
por: Matsubara, Mio, et al.
Publicado: (2020)

The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation
por: Shigemoto, Yumi, et al.
Publicado: (2021)

Short Axial Length Is Related to Asymmetric Vortex Veins in Central Serous Chorioretinopathy
por: Terao, Nobuhiro, et al.
Publicado: (2021)

The Genetic Background of Central Serous Chorioretinopathy: A Review on Central Serous Chorioretinopathy Genes
por: Giannopoulos, Konstantinos, et al.
Publicado: (2021)

Traumatic central serous chorioretinopathy
por: Ramchandani, Suresh, et al.
Publicado: (2015)

Traumatic central serous chorioretinopathy
por: Steeples, Laura, et al.
Publicado: (2015)

Atypical Central Serous Chorioretinopathy
por: Cebeci, Zafer, et al.
Publicado: (2017)

Biomarkers for central serous chorioretinopathy
por: Nkrumah, Gideon, et al.
Publicado: (2020)

Central Serous Chorioretinopathy Classification
por: Vilela, Manuel, et al.
Publicado: (2020)

Brachytherapy for Central Serous Chorioretinopathy
por: Arora, Supriya, et al.
Publicado: (2022)

Central serous chorioretinopathy in pregnancy
por: Ochinciuc, Radu, et al.
Publicado: (2022)

Central serous chorioretinopathy: Treatment
por: Park, Jong Beom, et al.
Publicado: (2022)

Genome-wide association analyses identify two susceptibility loci for pachychoroid disease central serous chorioretinopathy
por: Hosoda, Yoshikatsu, et al.
Publicado: (2019)

Successful Detection of the Characteristics of Tear Film Breakup Appearing Immediately after Eye Opening by Videokeratography with a Newly-Developed Indicator
por: Yokoi, Norihiko, et al.
Publicado: (2023)

Central serous chorioretinopathy secondary to trauma
por: Jackson, Thomas E., et al.
Publicado: (2012)

Central Serous Chorioretinopathy after Rhinoplasty
por: Moschos, Marilita M., et al.
Publicado: (2010)

Photodynamic Therapy and Central Serous Chorioretinopathy
por: Siaudvytyte, Lina, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_o158hjhlkh6ubu463v0c9052mc